BPC-157
Also referenced as: Body Protection Compound-157, PL 14736, pentadecapeptide BPC 157
The most discussed recovery peptide in wellness culture, and one of the clearest examples of a preclinical evidence base being read as clinical proof.
Quick answers
- What is BPC-157?
- BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in stomach juice. It is studied mainly for tissue repair, such as tendon, ligament, muscle and gut healing.
- What are the side effects of BPC-157?
- Human safety data are very limited. Animal studies report few adverse effects, but no large human trials have measured side effects. Product quality and contamination are extra risks with unregulated sources.
- Is BPC-157 legal or FDA approved?
- No. BPC-157 is not FDA approved for any use. In 2023 the FDA placed it on the list of substances that raise significant safety concerns for compounding, and WADA bans it in sport.
- Does BPC-157 work?
- Animal and lab studies show consistent healing signals, but there are almost no controlled human trials. Whether it works in people is unproven.
Educational summary, not medical advice. Sources are listed below.
- Evidence grade
- DPreclinical Research
Preclinical Research
- Regulatory status
- Not FDA Approved
Not approved for any indication. In the United States it was placed on the FDA's list of substances difficult to compound, and it is prohibited in sport under WADA rules.
- Human data
- Limited
No registered clinical trials identified
- Last reviewed
- September 1, 2026
Overview
BPC-157 is a synthetic 15-amino-acid sequence related to a fragment of human gastric juice protein BPC. Animal research has reported accelerated healing across tendon, muscle, gut, bone and nerve injury models.
The gap between that preclinical literature and human evidence is wide. Enthusiasm in fitness and longevity communities substantially exceeds what published human data can support.
Why It's Being Studied
- Tendon, ligament and muscle healing after injury in animal models.
- Gastrointestinal mucosal protection, including inflammatory bowel models, where early human work has been directed.
- Angiogenesis and nerve regeneration questions.
Mechanism of Action
In animals it appears to help new blood vessels and connective tissue form at an injury site, which speeds healing in those models.
Proposed mechanisms include upregulation of VEGF receptor 2 signalling and the FAK-paxillin pathway, modulation of nitric oxide systems, effects on growth hormone receptor expression in tendon fibroblasts, and interaction with the gut-brain axis. Most mechanistic work is rodent or in-vitro.
The stages of tissue repair
Tap each stage to see what happens.
Background: Recovery & Tissue Research
Tissue-repair peptide research looks at the stages of healing — inflammation, new blood-vessel growth, cell migration and remodelling — and asks whether a signal can speed or improve any of them.
Most of this literature is animal and cell work. Rodent tendon, gut and wound models heal quickly and differently from human tissue, so strong-looking preclinical results often do not translate.
Research Areas & Routes Studied
- Tendon and ligament healing
- Muscle injury
- Gastrointestinal mucosa
- Angiogenesis
- Nerve injury
- Subcutaneous injection (animal research)
- Intraperitoneal (animal research)
- Oral (animal research)
Evidence Summary
A large volume of animal research, much of it from a small number of research groups, with essentially no completed and published randomised human trials.
Higher tiers carry more weight. Filled tiers have evidence for BPC-157; tap to read it.
- Early-phase work in inflammatory bowel disease has been reported, but no adequately powered, published randomised trials establish efficacy for tendon, joint or muscle healing in people.
3 cited sources.
- Narrative review1
- Animal study1
- Regulatory document1
Human clinical evidence
- Early-phase work in inflammatory bowel disease has been reported, but no adequately powered, published randomised trials establish efficacy for tendon, joint or muscle healing in people.
Animal studies
- Numerous rat and mouse studies report faster healing of tendon, muscle, gut, bone and nerve injuries.
- A large share of this literature originates from a small number of affiliated research groups, which limits independent replication.
In-vitro studies
- Fibroblast and endothelial cell studies describing migration and growth factor signalling.
Anecdotal / community information
- Extensive first-person injury-recovery reports. These are uncontrolled, unblinded and cannot distinguish healing from natural recovery.
Reported Adverse Events in Research
- No systematic human safety dataset exists. Reported tolerability comes from animal studies and uncontrolled human reports.
- Because it promotes angiogenesis in animal models, its behaviour in the presence of undiagnosed malignancy is an open safety question.
- Research-use-only material carries independent risks of misidentification, contamination and incorrect concentration.
Limitations of Current Evidence
- Preclinical dominance: animal healing models are poor predictors of human musculoskeletal outcomes.
- Limited independent replication of the core findings.
- No established human dosing protocol exists.
How to Read This Research
- Was the study in humans, animals or cells?
- Was healing measured by function (strength, pain, movement) or only by tissue appearance?
- Was there a control group receiving the same care without the compound?
- Growth-promoting signals raise theoretical questions about unwanted growth; absence of reported harm in short animal studies is not proof of safety.
- Rodent injury models are often surgically created and heal in days — be cautious extrapolating time frames.
- Angiogenesis
- Formation of new blood vessels.
- Fibroblast
- A cell that produces collagen and connective tissue.
- Preclinical
- Research done before human testing — in animals or cells.
Compare With Other Compounds
| BPC-157 | TB-500 | |
|---|---|---|
| Evidence grade | D — Preclinical Research | D — Preclinical Research |
| Regulatory status | Not FDA Approved | Research Use Only |
| Human data | Limited | Limited |
| Clinical trials | None identified | None identified |
| Research routes | Subcutaneous injection (animal research), Intraperitoneal (animal research), Oral (animal research) | Subcutaneous injection (animal research), Topical (ophthalmic studies of the full protein) |
| Cited sources | 3 | 2 |
Frequently Asked Questions
Documented Research Protocols
BPC-157 — research context, not a human protocol
Set out what published research does and does not establish about BPC-157 administration, and why no human protocol can responsibly be summarised.
View documented protocol
Why It Is Used
- Recovery
Soft-Tissue Injury and Recovery
BPC-157 is the single most searched research peptide. The gap between how confidently it is discussed and what has been published in humans is the story here.
Read the case study
Research References
- Narrative review
Stable gastric pentapeptide BPC 157: tissue healing research review
Sikiric P, et al.- Main finding
- Summarises reported healing effects across multiple animal injury models.
- Limitations
- Review authored by the principal research group; not independent evidence and not human evidence.
- Animal study
BPC 157 in tendon healing (animal model)
- Regulatory document
FDA compounding category 2 bulk drug substances list
- Main finding
- BPC-157 appears among substances identified as raising significant safety risks in compounding.